Odevixibat Patent Expiration
Odevixibat is used for reducing serum bile acids and treating pruritus in patients with Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis. It was first introduced by Ipsen Biopharmaceuticals Inc
Odevixibat Patents
Given below is the list of patents protecting Odevixibat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bylvay | US10011633 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US10093697 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US10487111 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US10975046 | Crystal modifications of odevixibat | Jun 20, 2039 | Ipsen |
| Bylvay | US10981952 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US11365182 | Crystal modifications of odevixibat | Jun 20, 2039 | Ipsen |
| Bylvay | US11583539 | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors | Nov 12, 2041 | Ipsen |
| Bylvay | US11732006 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US11801226 | Pharmaceutical formulation of odevixibat | Jun 20, 2039 | Ipsen |
| Bylvay | US11802115 | Pharmaceutical formulation of odevixibat | Jun 20, 2039 | Ipsen |
| Bylvay | US7132416 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep 05, 2022
(Expired) | Ipsen |
| Bylvay | US9694018 | IBAT inhibitors for the treatment of liver disease | Nov 08, 2031 | Ipsen |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳